BlackRock, Inc. filed Amendment No. 4 to Schedule 13G with the SEC on October 27, 2026, disclosing its beneficial ownership position in Vir Biotechnology, Inc. as of the event date of September 30, 2026.

Key Highlights

  • Aggregate beneficial ownership: BlackRock reported 20,905,681 shares of Vir Biotechnology common stock beneficially owned, representing 12.4% of the class.
  • Sole voting power: BlackRock disclosed sole voting power over 20,560,285 shares.
  • Sole dispositive power: BlackRock reported sole dispositive power over all 20,905,681 shares.
  • No shared voting or dispositive power: Both shared voting power and shared dispositive power are reported as 0.
  • Event date: The triggering event date for this filing is September 30, 2026.
  • Filing entity: BlackRock, Inc., incorporated in Delaware, headquartered at 50 Hudson Yards, New York, NY 10001, filed as a parent holding company (type HC).

BlackRock's Amended Ownership Disclosure in Vir Biotechnology

According to the filing, BlackRock, Inc. submitted Amendment No. 4 to Schedule 13G regarding its holdings in Vir Biotechnology, Inc. (CUSIP 92764N102), whose principal executive offices are listed at 1800 Owens Street, Suite 900, San Francisco, CA 94158. The filing reflects a beneficial ownership position of 20,905,681 shares of common stock, equating to 12.4% of the outstanding class as of the September 30, 2026 event date.

The filing states that the reported holdings reflect securities beneficially owned, or deemed to be beneficially owned, by certain business units of BlackRock, Inc. and its subsidiaries and affiliates, described in the filing as the "Reporting Business Units," in accordance with SEC Release No. 34-39538 (January 12, 1998). The filing notes that securities beneficially owned by other business units whose beneficial ownership is disaggregated from that of the Reporting Business Units are not included.

With respect to the right to receive dividends or sale proceeds, the filing states that "various persons have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of the common stock of Vir Biotechnology, Inc." and that no single person's interest exceeds five percent of the total outstanding common shares. The filing was signed by Spencer Fleming, Managing Director, on October 27, 2026, and includes Exhibit 24 (Power of Attorney) and Exhibit 99 (Item 7 subsidiary identification).

What Was Disclosed

BlackRock, Inc. disclosed via an amended Schedule 13G that it beneficially owns 20,905,681 shares, or 12.4%, of Vir Biotechnology, Inc. common stock, with sole voting power over 20,560,285 shares and sole dispositive power over all reported shares, as of September 30, 2026.